EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis

Cindy X Zhang, Sharika Nuzhat, Md Ridwan Islam, Syed Jayedul Bashar, Subhasish Das, Rukaeya Amin, Firdausi Qadri, Farhana Khanam, Dilruba Ahmed, Patricia B Pavlinac, Mohammod Jobayer Chisti, Tahmeed Ahmed und 1 weitere

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70453 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Cindy X Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Dysentery, Bacillary, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing antimicrobial resistance poses a serious challenge for the treatment of Shigella infections, and there is an urgent need for alternative antibacterial treatments. We conducted a clinical trial to investigate the efficacy of oral tebipenem pivoxil, compared to intravenous ceftriaxone, in Bangladeshi children with shigellosis. Using demographic data of 2249 Bangladeshi children with suspected shigellosis, population pharmacokinetic (PK) simulations were conducted to simulate tebipenem PK profiles in children with the proposed dosing regimen. Subsequently, the model predictions estimated each virtual participant's fraction of time over the 3‐day treatment period during which simulated free tebipenem plasma concentration was above the minimum inhibitory concentration ( f T > MIC). Variability associated with the prevalence of different Shigella species in Bangladeshi children and the MIC distributions were incorporated. Shigella treatment effect was assumed for participants that had f T > MIC for at least 40% of the 3‐day treatment period (40% f T > MIC). The probability of achieving 40% f T > MIC was 86.4% for 4 mg/kg tebipenem pivoxil three times daily (TID) dosing and 92.4% with 3 mg/kg tebipenem pivoxil four times daily (QID) dosing. Lastly, the probability of tebipenem pivoxil being non‐inferior to ceftriaxone, in a clinical trial containing 66 participants per arm, was evaluated for two dosing regimens. Three levels of ceftriaxone resistance were simulated to examine how dynamic ceftriaxone resistance may impact the trial outcome. Our findings suggest that more frequent tebipenem pivoxil dosing may increase the chance of producing treatment effects, contribute valuable insights to inform dosing strategy selection, and demonstrate a workflow that can be adapted to other drugs and diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dysentery, BacillaryAnti-Bacterial AgentsCarbapenemsHumansMicrobial Sensitivity TestsMaleFemaleChildChild, PreschoolCeftriaxoneBangladeshInfantTreatment OutcomeShigellaAdministration, OralModels, BiologicalAdolescentComputer Simulation

Stichwörter der Autor:innen

PK/PDinfectious diseasespediatricspopulation pharmacokineticsshigellosis

Substanzen

Anti-Bacterial AgentsCarbapenemsCeftriaxonetebipenem

Autor:innen und Institutionen

  • Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
  • Clinical and Diagnostic Services, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka, Bangladesh.
  • Nutrition Research Division, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka, Bangladesh.
  • Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka, Bangladesh.
  • Department of Global Health, University of Washington, Seattle, Washington, USA.
  • Office of the Executive Director, International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka, Bangladesh.

ORCID-Profile: Samuel L M Arnold

Förderung

  • NIAID NIH HHS

Zitieren

APA

Zhang, C. X., Nuzhat, S., Islam, M. R., Bashar, S. J., Das, S., Amin, R., Qadri, F., Khanam, F., Ahmed, D., Pavlinac, P. B., Chisti, M. J., Ahmed, T., & Arnold, S. L. M. (2026). Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis. Clinical and Translational Science. https://doi.org/10.1111/cts.70453

Vancouver

Zhang CX, Nuzhat S, Islam MR, Bashar SJ, Das S, Amin R, et al. Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis. Clinical and Translational Science. 2026. doi:10.1111/cts.70453

BibTeX
@article{Zhang2026,
  author = {Zhang, Cindy X and Nuzhat, Sharika and Islam, Md Ridwan and Bashar, Syed Jayedul and Das, Subhasish and Amin, Rukaeya and Qadri, Firdausi and Khanam, Farhana and Ahmed, Dilruba and Pavlinac, Patricia B and Chisti, Mohammod Jobayer and Ahmed, Tahmeed and Arnold, Samuel L M},
  title = {Population Pharmacokinetic and Pharmacodynamic Prediction for Tebipenem Pivoxil Treatment of Pediatric Shigellosis},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70453}
}
Kostenlos starten →